drugset / Trial / NCT06417554
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.
Timeline
- Start
- 2024-05-13
- Primary completion
- 2027-07
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | SHR-A2102 | Other / unclassified | — | — |